尼莫拉唑联合放疗在基因特征判定的缺氧性头颈癌中获益的随机3期试验(NIMRAD)
NIMRAD是一项3期多中心安慰剂对照双盲试验,纳入不适合顺铂化疗或西妥昔单抗的头颈鳞癌患者,随机接受IMRT联合尼莫拉唑或安慰剂。在缺氧组中,尼莫拉唑未改善无局部区域进展生存(校正HR 0.72,95%CI 0.36-1.44,P=0.35)或总生存,全人群结果相似。尼莫拉唑组急性恶心发生率更高。
要点
- 在基因特征判定的缺氧性头颈鳞癌中,尼莫拉唑联合IMRT未改善无局部区域进展生存。
- 缺氧组中尼莫拉唑联合IMRT与安慰剂联合IMRT的总生存无显著差异(校正HR 0.96)。
- 尼莫拉唑联合IMRT较安慰剂联合IMRT引起更多急性恶心(G1+2 56.6% vs 42.4%,G3 10.1% vs 5.3%,P<0.05)。
核心结论
- 在老年且不适合顺铂或西妥昔单抗的局部晚期头颈鳞癌患者中,IMRT联合尼莫拉唑未改善局部区域控制或生存。
研究设计与样本
- NIMRAD为3期、多中心、安慰剂对照、双盲试验(NCT01950689),在英国19个中心于2014年5月至2019年5月随机分配338例不适合同期铂类化疗或西妥昔单抗的头颈鳞癌患者。
- 患者1:1随机接受IMRT(65 Gy/30次/6周)联合尼莫拉唑(1.2 g/m2每日,IMRT前)或安慰剂。
- 主要终点为缺氧肿瘤患者的无局部区域进展生存,缺氧定义为使用经验证的26基因特征得出的肿瘤缺氧评分大于或等于前50例分析患者的中位值(≥0.079)。
- 计划样本量340例,假设缺氧组尼莫拉唑的HR为0.50,需66例局部区域失败以在双侧log-rank检验5%显著性水平下达到80%把握度。
- 中位随访3.1年(95%CI 2.9-3.4),286例(85%)可获缺氧评分;患者中位年龄73岁(范围44-88;IQR 70-76)。
主要发现
- 缺氧组中尼莫拉唑联合IMRT与安慰剂联合IMRT相比,无局部区域进展生存无显著改善(校正HR 0.72;95%CI 0.36-1.44;P=0.35),总生存也无显著改善(校正HR 0.96;95%CI 0.53-1.72;P=0.88)。
- 缺氧组共发生36例(25.9%)局部区域失败。
- 全人群中尼莫拉唑联合IMRT同样未改善无局部区域进展生存或总生存。
- 分配至尼莫拉唑的患者中,73%在至少50%的IMRT分次期间坚持用药。
- 尼莫拉唑联合IMRT较安慰剂联合IMRT引起更多急性恶心(CTCAE 4.0版G1+2:56.6% vs 42.4%;G3:10.1% vs 5.3%;P<0.05)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Tumor hypoxia is an adverse prognostic factor in head and neck squamous cell carcinoma (HNSCC). We assessed whether patients with hypoxic HNSCC benefited from the addition of nimorazole to definitive intensity modulated radiation therapy (IMRT). METHODS AND MATERIALS: NIMRAD was a phase 3, multicenter, placebo-controlled, double-anonymized trial of patients with HNSCC unsuitable for concurrent platinum chemotherapy or cetuximab with definitive IMRT (NCT01950689). Patients were randomized 1:1 to receive IMRT (65 Gy in 30 fractions over 6 weeks) plus nimorazole (1.2 g/m2 daily, before IMRT) or placebo. The primary endpoint was freedom from locoregional progression (FFLRP) in patients with hypoxic tumors, defined as greater than or equal to the median tumor hypoxia score of the first 50 patients analyzed (≥0.079), using a validated 26-gene signature. The planned sample size was 340 patients, allowing for signature generation in 85% and an assumed hazard ratio (HR) of 0.50 for nimorazole effectiveness in the hypoxic group and requiring 66 locoregional failures to have 80% power in a 2-tail log-rank test at the 5% significance level. RESULTS: Three hundred thirty-eight patients were randomized by 19 centers in the United Kingdom from May 2014 to May 2019, with a median follow-up of 3.1 years (95% CI, 2.9-3.4). Hypoxia scores were available for 286 (85%). The median patient age was 73 years (range, 44-88; IQR, 70-76). There were 36 (25.9%) locoregional failures in the hypoxic group, in which nimorazole + IMRT did not improve FFLRP (adjusted HR, 0.72; 95% CI, 0.36-1.44; P = .35) or overall survival (adjusted HR, 0.96; 95% CI, 0.53-1.72; P = .88) compared with placebo + IMRT. Similarly, nimorazole + IMRT did not improve FFLRP or overall survival in the whole population. In total (N = 338), 73% of patients allocated nimorazole adhered to the drug for ≥50% of IMRT fractions. Nimorazole + IMRT caused more acute nausea compared with placebo + IMRT (Common Terminology Criteria for Adverse Events version 4.0 G1+2: 56.6% vs 42.4%, G3: 10.1% vs 5.3%, respectively; P < .05). CONCLUSIONS: Addition of the hypoxia modifier nimorazole to IMRT for locally advanced HNSCC in older and less fit patients did not improve locoregional control or survival.
引用
- Thomson DJ, Slevin NJ, Baines H, et al. Randomized Phase 3 Trial of the Hypoxia Modifier Nimorazole Added to Radiation Therapy With Benefit Assessed in Hypoxic Head and Neck Cancers Determined Using a Gene Signature (NIMRAD). Int J Radiat Oncol Biol Phys. 2023. PMID: 38072326. doi:10.1016/j.ijrobp.2023.11.055
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。